MA41197B1 - Traitement de le pemphigus - Google Patents
Traitement de le pemphigusInfo
- Publication number
- MA41197B1 MA41197B1 MA41197A MA41197A MA41197B1 MA 41197 B1 MA41197 B1 MA 41197B1 MA 41197 A MA41197 A MA 41197A MA 41197 A MA41197 A MA 41197A MA 41197 B1 MA41197 B1 MA 41197B1
- Authority
- MA
- Morocco
- Prior art keywords
- pemphigus
- corticosteroids
- therapy
- relates
- present
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Abstract
La présente invention concerne des procédés de traitement, avec un inhibiteur de btk, d'une maladie bulleuse, en particulier du pemphigus vulgaire ou du pemphigus foliacé chez un mammifère, l'utilisation d'un inhibiteur de btk en tant que thérapie de remplacement d'une thérapie par corticoïdes pour les maladies pouvant être traitées avec des corticoïdes, telles qu'une maladie auto-immune ou une maladie inflammatoire et en particulier lorsque des corticoïdes sont utilisés comme thérapie de première ou de seconde ligne. La présente invention concerne également des formulations pharmaceutiques comprenant ces inhibiteurs de btk.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462093891P | 2014-12-18 | 2014-12-18 | |
PCT/US2015/066868 WO2016100914A1 (fr) | 2014-12-18 | 2015-12-18 | Traitement du pemphigus |
Publications (1)
Publication Number | Publication Date |
---|---|
MA41197B1 true MA41197B1 (fr) | 2021-01-29 |
Family
ID=55080225
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA41197A MA41197B1 (fr) | 2014-12-18 | 2015-12-18 | Traitement de le pemphigus |
Country Status (15)
Country | Link |
---|---|
US (2) | US10485797B2 (fr) |
EP (1) | EP3233103B1 (fr) |
CN (1) | CN107257686B (fr) |
AU (2) | AU2015364335B2 (fr) |
BR (1) | BR112017013022A2 (fr) |
CA (1) | CA2970723C (fr) |
EA (1) | EA036269B1 (fr) |
ES (1) | ES2843323T3 (fr) |
IL (1) | IL252839B (fr) |
MA (1) | MA41197B1 (fr) |
MX (1) | MX2017007973A (fr) |
PL (1) | PL3233103T3 (fr) |
PT (1) | PT3233103T (fr) |
SG (1) | SG11201704808VA (fr) |
WO (1) | WO2016100914A1 (fr) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
LT3181567T (lt) | 2012-09-10 | 2019-07-25 | Principia Biopharma Inc. | Pirazolpirimidino junginiai kaip kinazės slopikliai |
PL2989106T3 (pl) | 2013-04-25 | 2017-08-31 | Beigene, Ltd. | Połączone związki heterocykliczne jako inhibitory kinazy białkowej |
KR102100419B1 (ko) | 2013-09-13 | 2020-04-14 | 베이진 스위찰랜드 게엠베하 | 항-pd1 항체 및 이의 치료 및 진단 용도 |
MX2016010754A (es) | 2014-02-21 | 2017-03-03 | Principia Biopharma Inc | Sales y forma solida de un inhibidor btk. |
CN106604742B (zh) | 2014-07-03 | 2019-01-11 | 百济神州有限公司 | 抗pd-l1抗体及其作为治疗剂及诊断剂的用途 |
SG11201704808VA (en) | 2014-12-18 | 2017-07-28 | Principia Biopharma Inc | Treatment of pemphigus |
TW201718572A (zh) | 2015-06-24 | 2017-06-01 | 普林斯匹亞生物製藥公司 | 酪胺酸激酶抑制劑 |
IL293621B2 (en) | 2016-06-29 | 2023-09-01 | Principia Biopharma Inc | Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[4,3-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4 -Methyl-4-[4-(oxane-3-yl)piperazine-1-yl)penta-2-ananitrile |
WO2018007885A1 (fr) | 2016-07-05 | 2018-01-11 | Beigene, Ltd. | Association d'un antagoniste de pd-1 et d'un inhibiteur du raf pour le traitement du cancer. |
CN116478166A (zh) | 2016-08-16 | 2023-07-25 | 百济神州(苏州)生物科技有限公司 | 一种化合物的晶型、其制备和用途 |
AU2017313085A1 (en) | 2016-08-19 | 2019-03-14 | Beigene Switzerland Gmbh | Use of a combination comprising a Btk inhibitor for treating cancers |
CN110446710B (zh) * | 2016-12-15 | 2022-08-02 | 豪夫迈·罗氏有限公司 | 制备btk抑制剂的方法 |
CN108329274B (zh) * | 2017-01-13 | 2021-09-03 | 正大天晴药业集团股份有限公司 | 布鲁顿酪氨酸激酶抑制剂 |
EP3573989A4 (fr) * | 2017-01-25 | 2020-11-18 | Beigene, Ltd. | Formes cristallines de (s) -7- (1- (but-2-ynoyl) pipéridin-4-yl) -2- (4-phénoxyphényl) -4, 5, 6, 7-tétrahy dropyrazolo [1, 5-a]pyrimidine-3-carboxamide, préparation et utilisations associées |
CN108727404B (zh) * | 2017-04-14 | 2020-05-12 | 中国科学院上海药物研究所 | 噻吩并[3,2-d]嘧啶类化合物、其制备方法及用途 |
EP3645569A4 (fr) | 2017-06-26 | 2021-03-24 | BeiGene, Ltd. | Immunothérapie pour carcinome hépatocellulaire |
WO2019034009A1 (fr) | 2017-08-12 | 2019-02-21 | Beigene, Ltd. | Inhibiteur de btk ayant une double sélectivité améliorée |
US11786529B2 (en) | 2017-11-29 | 2023-10-17 | Beigene Switzerland Gmbh | Treatment of indolent or aggressive B-cell lymphomas using a combination comprising BTK inhibitors |
EP3789040A4 (fr) * | 2018-04-27 | 2022-03-09 | ONO Pharmaceutical Co., Ltd. | Agent préventif et/ou thérapeutique pour maladie auto-immune comprenant un composé ayant une activité inhibitrice de btk en tant que principe actif |
SG11202102116XA (en) | 2018-09-18 | 2021-04-29 | Beijing Innocare Pharma Tech Co Ltd | Crystalline forms of 6- (1-acryloylpiperidin-4-yl) -2- (4-phenoxyphenyl) nicotinamide |
WO2020093896A1 (fr) * | 2018-11-06 | 2020-05-14 | Beijing Innocare Pharma Tech Co., Ltd. | Dispersion solide amorphe de 6-(1-acryloylpipéridine-4-yl)-2-(4-phénoxyphényl) nicotinamide |
CN109939223B (zh) * | 2019-04-04 | 2020-04-07 | 中南大学湘雅二医院 | 一种白介素2在制备用于治疗寻常型天疱疮口腔糜烂药物的应用 |
EP4041240A1 (fr) | 2019-10-09 | 2022-08-17 | Principia Biopharma Inc. | Procédés de traitement du pemphigus par administration de (r)-2-[3-[4-amino-3-(2-fluoro-4-phénoxy-phényl)pyrazolo[3,4-d]pyrimidin-1-yl]pipéridine-1-carbonyl]-4-méthyl-4-[4-(oxétan-3-yl)pipérazin-1-yl]pent-2-ène-nitrile |
CN115209899A (zh) | 2019-10-14 | 2022-10-18 | 普林斯匹亚生物制药公司 | 通过施用(R)-2-[3-[4-氨基-3-(2-氟-4-苯氧基-苯基)吡唑并[3,4-d]嘧啶-1-基]哌啶-1-羰基]-4-甲基-4-[4-(氧杂环丁-3-基)哌嗪-1-基]戊-2-烯腈治疗免疫性血小板减少症的方法 |
AU2021205248A1 (en) * | 2020-01-08 | 2022-09-01 | Principia Biopharma Inc. | Topical pharmaceutical compositions comprising 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4,4-dimethylpent-2-enenitrile |
WO2021207662A1 (fr) * | 2020-04-10 | 2021-10-14 | Genentech, Inc. | Utilisation d'il-22-fc pour le traitement ou la prévention de la pneumonie, du syndrome de détresse respiratoire aiguë ou du syndrome de libération de cytokines |
AU2022257016A1 (en) | 2021-04-16 | 2023-11-30 | Principia Biopharma, Inc. | Methods for treating drug and vaccine induced immune thrombocytopenia by administering specific compounds |
US11786531B1 (en) | 2022-06-08 | 2023-10-17 | Beigene Switzerland Gmbh | Methods of treating B-cell proliferative disorder |
Family Cites Families (123)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4082819A (en) | 1977-03-02 | 1978-04-04 | The Standard Oil Company | Rubber-modified acrylonitrile-vinyl ether-indene polymers |
JPS5663950A (en) | 1979-10-30 | 1981-05-30 | Mitsubishi Chem Ind Ltd | Cyclopropanecarboxylic ester |
FR2535721A1 (fr) | 1982-11-08 | 1984-05-11 | Sanofi Sa | Derives de la piperidinedione protecteurs du myocarde presentant une acticite antiarythmique, leur procede de preparation et les medicaments qui contiennent lesdits derives |
US4911920A (en) | 1986-07-30 | 1990-03-27 | Alcon Laboratories, Inc. | Sustained release, comfort formulation for glaucoma therapy |
JPS623848A (ja) | 1985-06-28 | 1987-01-09 | Nippon Steel Corp | 疲労強度のすぐれたスタツド付きフラツシユバツト溶接アンカ−チエ−ン |
FR2588189B1 (fr) | 1985-10-03 | 1988-12-02 | Merck Sharp & Dohme | Composition pharmaceutique de type a transition de phase liquide-gel |
JP2518353B2 (ja) | 1988-06-09 | 1996-07-24 | 住友化学工業株式会社 | シアノ酢酸アミド誘導体およびその製造中間体 |
CA2018801C (fr) | 1990-06-12 | 2000-08-22 | Pierre Louis Beaulieu | Derives peptidiques comprenant une terminaison-n1,4-dioxo-c4 |
JPH04177244A (ja) | 1990-11-10 | 1992-06-24 | Konica Corp | ハロゲン化銀写真感光材料 |
CA2033447C (fr) | 1990-12-31 | 1999-08-31 | Robert Deziel | Complexe synergique pour le traitement des infections herpetiques |
EP0495421B1 (fr) | 1991-01-15 | 1996-08-21 | Alcon Laboratories, Inc. | Utilisation de carragheenane dans des compositions ophthalmologiques topiques |
US5212162A (en) | 1991-03-27 | 1993-05-18 | Alcon Laboratories, Inc. | Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions |
JPH05301838A (ja) | 1991-10-15 | 1993-11-16 | Mitsubishi Kasei Corp | スチレン誘導体 |
US5792771A (en) | 1992-11-13 | 1998-08-11 | Sugen, Inc. | Quinazoline compounds and compositions thereof for the treatment of disease |
WO1995024190A2 (fr) | 1994-03-07 | 1995-09-14 | Sugen, Inc. | Inhibiteurs de tyrosine-kinase receptrice destines a inhiber les troubles lies a la proliferation cellulaire et compositions les contenant |
JPH0827090A (ja) | 1994-05-13 | 1996-01-30 | Sumitomo Chem Co Ltd | シアノ酢酸アミド誘導体、その用途およびその製造中間体 |
US6331555B1 (en) | 1995-06-01 | 2001-12-18 | University Of California | Treatment of platelet derived growth factor related disorders such as cancers |
DE59808284D1 (de) | 1997-03-14 | 2003-06-12 | Basf Ag | Cycloalkylalkancarbonsäureamide, deren herstellung und verwendung |
US7863444B2 (en) | 1997-03-19 | 2011-01-04 | Abbott Laboratories | 4-aminopyrrolopyrimidines as kinase inhibitors |
IL125947A0 (en) | 1997-09-17 | 1999-04-11 | American Cyanamid Co | 3-(1,2-benzisothiazol- and isoxazol-5-yl)-2,4(1h,3h)-pyrimidinedione or thione and 3-(1,2-benzisothiazol- and isoxazol-5-yl)-4(3)-pyrimidinone or thione herbicidal agents |
TR200000944T2 (tr) | 1997-10-09 | 2000-11-21 | Perio Products Ltd. | Geciktirmeli tam çözünümlü mide-bağırsak bölgesi ilaç verme sistemi. |
US6713474B2 (en) | 1998-09-18 | 2004-03-30 | Abbott Gmbh & Co. Kg | Pyrrolopyrimidines as therapeutic agents |
CN101481359A (zh) | 1999-04-15 | 2009-07-15 | 布里斯托尔-迈尔斯斯奎布公司 | 环状蛋白酪氨酸激酶抑制剂 |
CA2385747A1 (fr) | 1999-09-17 | 2001-03-22 | Gavin C. Hirst | Pyrazolopyrimidines en tant qu'agents therapeutiques |
AU2000240570A1 (en) | 2000-03-29 | 2001-10-08 | Knoll Gesellschaft Mit Beschraenkter Haftung | Pyrrolopyrimidines as tyrosine kinase inhibitors |
AR042586A1 (es) | 2001-02-15 | 2005-06-29 | Sugen Inc | 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa |
MXPA03008560A (es) | 2001-03-22 | 2004-06-30 | Abbot Gmbh & Co Kg | Pirazolopirimidinas como agentes terapeuticos. |
EP1451173A4 (fr) | 2001-11-01 | 2005-10-26 | Icagen Inc | Piperidines |
JP3991812B2 (ja) | 2001-12-11 | 2007-10-17 | 住友化学株式会社 | エステル化合物およびその用途 |
WO2003068157A2 (fr) | 2002-02-11 | 2003-08-21 | The Brigham And Women's Hospital, Inc. | Inhibiteurs de kinase et leurs procedes d'utilisation |
NI200300043A (es) | 2002-03-28 | 2003-11-05 | Warner Lambert Co | AMINOACIDOS CON AFINIDAD POR LA PROTEINA a2DELTA. |
FR2842735B1 (fr) | 2002-07-26 | 2006-01-06 | Flamel Tech Sa | Microcapsules a liberation modifiee de principes actifs peu solubles pour l'administration per os |
US7419981B2 (en) | 2002-08-15 | 2008-09-02 | Pfizer Inc. | Synergistic combinations of an alpha-2-delta ligand and a cGMP phosphodieterse 5 inhibitor |
GB0219024D0 (en) | 2002-08-15 | 2002-09-25 | Pfizer Ltd | Synergistic combinations |
GB0226370D0 (en) | 2002-11-12 | 2002-12-18 | Novartis Ag | Organic compounds |
MXPA05008878A (es) | 2003-02-21 | 2005-10-05 | Pfizer | Derivados de aminotiazol sustituidos con cicloalquilo que contiene n y composiciones farmaceuticas para inhibir la proliferacion celular, y metodos para su uso. |
WO2004100868A2 (fr) | 2003-04-23 | 2004-11-25 | Abbott Laboratories | Procede servant a traiter le rejet d'un transplant |
CA2533763C (fr) | 2003-08-01 | 2012-11-20 | Chugai Seiyaku Kabushiki Kaisha | Composes de cyanoamide utiles en tant qu'inhibiteurs de malonyl-coa decarboxylase |
KR20090080143A (ko) | 2003-09-02 | 2009-07-23 | 화이자 프로덕츠 인크. | 지프라시돈의 지속 방출형 투여 형태 |
WO2005023773A1 (fr) | 2003-09-04 | 2005-03-17 | Pfizer Limited | Procede pour la preparation d'arylpyrazoles substitues |
GB0322140D0 (en) | 2003-09-22 | 2003-10-22 | Pfizer Ltd | Combinations |
RU2344121C2 (ru) | 2003-09-25 | 2009-01-20 | УОРНЕР-ЛАМБЕРТ КОМПАНИ Эл-Эл-Си | Способы лечения заболеваний у млекопитающих |
US20060025383A1 (en) | 2004-02-03 | 2006-02-02 | Neil Wishart | Aminobenzoxazoles as therapeutic agents |
JP4552456B2 (ja) | 2004-02-27 | 2010-09-29 | 住友化学株式会社 | エステル化合物およびその用途 |
JPWO2005085210A1 (ja) | 2004-03-10 | 2008-01-17 | 小野薬品工業株式会社 | ニトリル化合物およびその化合物を有効成分として含有する医薬組成物 |
US7807719B2 (en) | 2004-09-14 | 2010-10-05 | Chaim Roifman | Compounds useful for modulating abnormal cell proliferation |
US20060079494A1 (en) | 2004-09-27 | 2006-04-13 | Santi Daniel V | Specific kinase inhibitors |
JP2008530113A (ja) | 2005-02-11 | 2008-08-07 | コーリー ファーマシューティカル グループ,インコーポレイテッド | オキシムおよびヒドロキシラミン置換イミダゾ[4,5−c]環化合物および方法 |
US20080260818A1 (en) | 2005-03-28 | 2008-10-23 | Dexcel Pharma Technologies Ltd. | Controlled Absorption of Statins in the Intestine |
EP2540296A1 (fr) | 2005-06-03 | 2013-01-02 | Xenon Pharmaceuticals Inc. | Dérivés d'arminothiazole utilisés comme inhibiteurs de la stéaroyl-coa désaturase humaine |
US20080176865A1 (en) | 2005-06-15 | 2008-07-24 | Pfizer Limited | Substituted arylpyrazoles |
US20080146643A1 (en) | 2005-06-15 | 2008-06-19 | Pfizer Limited | Combination |
US7645786B2 (en) | 2005-06-15 | 2010-01-12 | Pfizer Inc. | Substituted arylpyrazoles |
BRPI0611798A2 (pt) | 2005-06-15 | 2009-01-13 | Pfizer Ltd | compostos de arilpirazàis substituÍdos, sua composiÇço farmacÊutica e uso |
US20070149464A1 (en) | 2005-06-15 | 2007-06-28 | Pfizer Inc. | Combination |
GB0517205D0 (en) | 2005-08-22 | 2005-09-28 | Novartis Ag | Organic compounds |
CA2623327A1 (fr) | 2005-10-07 | 2007-04-19 | Kissei Pharmaceutical Co., Ltd. | Compose heterocyclique azote et composition pharmaceutique le contenant |
EP1957078B1 (fr) | 2005-12-02 | 2013-08-28 | Bayer HealthCare, LLC | Dérivés de pyrrolotriazine utiles pour traiter le cancer par inhibition de la kinase aurora |
JP2009523724A (ja) | 2006-01-13 | 2009-06-25 | ファーマサイクリクス,インコーポレイテッド | チロシンキナーゼ阻害剤およびその使用方法 |
AU2007234455B2 (en) | 2006-03-31 | 2012-10-04 | The Board Of Regents Of The University Of Texas System | Orally bioavailable caffeic acid related anticancer drugs |
US7645748B2 (en) | 2006-04-03 | 2010-01-12 | Forbes Medi-Tech Inc. | Sterol/stanol phosphorylnitroderivatives and use thereof |
CA2653941C (fr) | 2006-05-31 | 2013-01-08 | The Regents Of The University Of California | Derives d'aminopurine substitues et leurs utilisations |
US20100292229A1 (en) | 2006-06-30 | 2010-11-18 | The Board Of Regents Of The University Of Texas System | Tryphostin-analogs for the treatment of cell proliferative diseases |
BRPI0713555A2 (pt) | 2006-07-06 | 2012-03-20 | Array Biopharma, Inc. | ciclopenta [d] pirimidinas como inibidores de akt protéina cinase |
HUE031334T2 (hu) | 2006-09-22 | 2017-07-28 | Pharmacyclics Llc | Bruton-tirozinkináz inhibitorok |
US8987233B2 (en) | 2006-11-03 | 2015-03-24 | Pharmacyclics, Inc. | Bruton's tyrosine kinase activity probe and method of using |
CN101541767A (zh) | 2006-11-23 | 2009-09-23 | 诺瓦提斯公司 | 嘧啶类物质及其作为cxcr2受体拮抗剂的应用 |
WO2008116064A2 (fr) | 2007-03-21 | 2008-09-25 | Bristol-Myers Squibb Company | Composés hétérocycliques fusionnés utiles en tant que modulateurs de kinases |
GB2447933A (en) | 2007-03-27 | 2008-10-01 | Chemence Ltd | Cyanoacrylate monomer for forming an adhesive polymer |
SG10202107066WA (en) | 2007-03-28 | 2021-07-29 | Pharmacyclics Llc | Inhibitors of bruton's tyrosine kinase |
JP5529049B2 (ja) | 2008-02-25 | 2014-06-25 | エフ.ホフマン−ラ ロシュ アーゲー | ピロロピラジンキナーゼ阻害剤 |
WO2009106442A1 (fr) | 2008-02-25 | 2009-09-03 | F. Hoffmann-La Roche Ag | Inhibiteurs de la pyrrolopyrazine kinase |
KR101324804B1 (ko) | 2008-05-13 | 2013-11-01 | 아이알엠 엘엘씨 | 키나제 억제제로서의 질소 함유 융합 헤테로사이클 및 그의 조성물 |
CA2724715A1 (fr) | 2008-05-22 | 2009-11-26 | Amgen Inc. | Heterocycles en tant qu'inhibiteurs de proteine kinase |
EP3311818A3 (fr) | 2008-07-16 | 2018-07-18 | Pharmacyclics, LLC | Inhibiteurs de tyrosine-kinase de bruton pour le traitement de tumeurs solides |
MX2011001259A (es) | 2008-08-01 | 2011-03-15 | Biocryst Pharm Inc | Derivados de piperidina como inhibidores jak3. |
US8450337B2 (en) | 2008-09-30 | 2013-05-28 | Moleculin, Llc | Methods of treating skin disorders with caffeic acid analogs |
US20100113520A1 (en) | 2008-11-05 | 2010-05-06 | Principia Biopharma, Inc. | Kinase knockdown via electrophilically enhanced inhibitors |
US20120028981A1 (en) | 2008-11-05 | 2012-02-02 | Principia Biopharma Inc. | Kinase Knockdown Via Electrophilically Enhanced Inhibitors |
US8426428B2 (en) | 2008-12-05 | 2013-04-23 | Principia Biopharma, Inc. | EGFR kinase knockdown via electrophilically enhanced inhibitors |
AU2010292198A1 (en) | 2009-09-09 | 2012-04-05 | Celgene Avilomics Research, Inc. | PI3 kinase inhibitors and uses thereof |
US7718662B1 (en) | 2009-10-12 | 2010-05-18 | Pharmacyclics, Inc. | Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase |
CN102711765A (zh) | 2009-11-16 | 2012-10-03 | 加利福尼亚大学董事会 | 激酶抑制剂 |
JP2013529204A (ja) | 2010-05-20 | 2013-07-18 | エフ.ホフマン−ラ ロシュ アーゲー | ピロロ[2,3−b]ピラジン−7−カルボキサミド誘導体とJAK及びSYK及び阻害剤としてのそれらの使用 |
SG185617A1 (en) | 2010-05-31 | 2012-12-28 | Ono Pharmaceutical Co | Purinone derivative |
CN107898791A (zh) | 2010-06-03 | 2018-04-13 | 药品循环有限责任公司 | 布鲁顿酪氨酸激酶(btk)抑制剂的应用 |
US20120071497A1 (en) | 2010-06-03 | 2012-03-22 | Pharmacyclics, Inc. | Methods of treating abc-dlbcl using inhibitors of bruton's tyrosine kinase |
CN101880243A (zh) | 2010-06-04 | 2010-11-10 | 贵阳柏丝特化工有限公司 | 一种含氟氰拟除虫菊酯化合物及其合成方法与用途 |
US8563568B2 (en) | 2010-08-10 | 2013-10-22 | Celgene Avilomics Research, Inc. | Besylate salt of a BTK inhibitor |
CA2836410C (fr) | 2011-05-17 | 2019-08-20 | Principia Biopharma Inc. | Inhibiteurs de tyrosine kinases |
KR102052670B1 (ko) | 2011-05-17 | 2019-12-06 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 키나아제 저해제 |
WO2012158795A1 (fr) | 2011-05-17 | 2012-11-22 | Principia Biopharma Inc. | Dérivés de pyrazolopyrimidine utilisés comme inhibiteurs de tyrosine kinase |
WO2012158810A1 (fr) | 2011-05-17 | 2012-11-22 | Principia Biopharma Inc. | Inhibiteurs de tyrosine kinase |
US8828426B2 (en) | 2011-06-07 | 2014-09-09 | Zx Pharma, Llc | Multiparticulate L-carnitine compositions and related methods |
CA2840413A1 (fr) | 2011-06-28 | 2013-01-03 | Pharmacyclics, Inc. | Procedes et compositions visant a inhiber la resorption osseuse |
KR20140048968A (ko) | 2011-07-13 | 2014-04-24 | 파마시클릭스, 인코포레이티드 | 브루톤형 티로신 키나제의 억제제 |
WO2013010869A1 (fr) | 2011-07-19 | 2013-01-24 | Msd Oss B.V. | 4-imidazopyridazin-1-yl-benzamides et 4-imidazotriazin-1-yl-benzamides inhibiteurs de btk |
EP2548877A1 (fr) | 2011-07-19 | 2013-01-23 | MSD Oss B.V. | Dérivés de 4-(pyridine condensée à 5 chaînons)benzamide comme inhibiteurs de BTK |
CN103889987B (zh) * | 2011-07-19 | 2016-09-14 | 默沙东有限责任公司 | 作为btk抑制剂的选择的咪唑并吡嗪类 |
CA2849340A1 (fr) | 2011-09-20 | 2013-03-28 | Cellzome Limited | Derives de pyrazolo[4,3-c]pyridine comme inhibiteurs de kinases |
BR112014009276A8 (pt) | 2011-10-19 | 2017-06-20 | Pharmacyclics Inc | uso de inibidores de tirosina quinase de bruton (btk) |
US8377946B1 (en) | 2011-12-30 | 2013-02-19 | Pharmacyclics, Inc. | Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors |
US8501724B1 (en) | 2012-01-31 | 2013-08-06 | Pharmacyclics, Inc. | Purinone compounds as kinase inhibitors |
WO2013185082A2 (fr) | 2012-06-08 | 2013-12-12 | Biogen Idec Ma Inc. | Inhibiteurs de la tyrosine kinase de bruton |
CN104487441B (zh) | 2012-06-18 | 2018-06-01 | 普林斯匹亚生物制药公司 | 有用于治疗癌症和自身免疫性疾病的可逆的共价吡咯并嘧啶或吡唑并嘧啶 |
WO2014004707A1 (fr) | 2012-06-29 | 2014-01-03 | Principia Biopharma Inc. | Formulations comprenant de l'ibrutinib |
US9572811B2 (en) | 2012-08-03 | 2017-02-21 | Principia Biopharma Inc. | Treatment of dry eye |
LT3181567T (lt) | 2012-09-10 | 2019-07-25 | Principia Biopharma Inc. | Pirazolpirimidino junginiai kaip kinazės slopikliai |
GEP201606597B (en) | 2012-11-02 | 2017-01-10 | Pfizer | Bruton's tyrosine kinase inhibitors |
CN104854107A (zh) | 2012-11-15 | 2015-08-19 | 药品循环公司 | 作为激酶抑制剂的吡咯并嘧啶化合物 |
US20140142099A1 (en) | 2012-11-20 | 2014-05-22 | Principia Biopharma Inc. | Purinone Derivatives as Tyrosine Kinase Inhibitors |
JO3377B1 (ar) | 2013-03-11 | 2019-03-13 | Takeda Pharmaceuticals Co | مشتقات بيريدينيل وبيريدينيل مندمج |
US8957080B2 (en) | 2013-04-09 | 2015-02-17 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
BR112016016844A2 (pt) | 2014-02-03 | 2017-08-08 | Cadila Healthcare Ltd | Compostos heterocíclicos |
MX2016010754A (es) | 2014-02-21 | 2017-03-03 | Principia Biopharma Inc | Sales y forma solida de un inhibidor btk. |
SG11201704808VA (en) | 2014-12-18 | 2017-07-28 | Principia Biopharma Inc | Treatment of pemphigus |
US20180193274A1 (en) | 2014-12-24 | 2018-07-12 | Principia Biopharma Inc. | Compositions for ileo-jejunal drug delivery |
EP3236953B1 (fr) | 2014-12-24 | 2020-11-11 | Principia Biopharma Inc. | Dosage spécifique de site d'un inhibiteur de btk |
SG10201912443XA (en) | 2015-06-03 | 2020-02-27 | Principia Biopharma Inc | Tyrosine kinase inhibitors |
TW201718572A (zh) | 2015-06-24 | 2017-06-01 | 普林斯匹亞生物製藥公司 | 酪胺酸激酶抑制劑 |
CN105753863B (zh) | 2015-09-11 | 2018-07-31 | 东莞市真兴贝特医药技术有限公司 | 氧代二氢咪唑并吡啶类化合物及其应用 |
CN108349940B (zh) | 2015-10-14 | 2021-08-13 | 淄博百极常生制药有限公司 | 布鲁顿酪氨酸激酶抑制剂 |
IL293621B2 (en) | 2016-06-29 | 2023-09-01 | Principia Biopharma Inc | Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[4,3-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4 -Methyl-4-[4-(oxane-3-yl)piperazine-1-yl)penta-2-ananitrile |
-
2015
- 2015-12-18 SG SG11201704808VA patent/SG11201704808VA/en unknown
- 2015-12-18 WO PCT/US2015/066868 patent/WO2016100914A1/fr active Application Filing
- 2015-12-18 CN CN201580076193.1A patent/CN107257686B/zh active Active
- 2015-12-18 PT PT158231076T patent/PT3233103T/pt unknown
- 2015-12-18 MX MX2017007973A patent/MX2017007973A/es unknown
- 2015-12-18 EA EA201791243A patent/EA036269B1/ru not_active IP Right Cessation
- 2015-12-18 CA CA2970723A patent/CA2970723C/fr active Active
- 2015-12-18 PL PL15823107T patent/PL3233103T3/pl unknown
- 2015-12-18 US US15/537,294 patent/US10485797B2/en active Active
- 2015-12-18 AU AU2015364335A patent/AU2015364335B2/en active Active
- 2015-12-18 EP EP15823107.6A patent/EP3233103B1/fr active Active
- 2015-12-18 BR BR112017013022A patent/BR112017013022A2/pt active Search and Examination
- 2015-12-18 MA MA41197A patent/MA41197B1/fr unknown
- 2015-12-18 ES ES15823107T patent/ES2843323T3/es active Active
-
2017
- 2017-06-12 IL IL252839A patent/IL252839B/en active IP Right Grant
-
2019
- 2019-10-04 US US16/593,352 patent/US10946008B2/en active Active
-
2020
- 2020-11-05 AU AU2020264338A patent/AU2020264338A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EA201791243A1 (ru) | 2017-12-29 |
BR112017013022A2 (pt) | 2018-02-27 |
AU2020264338A1 (en) | 2020-12-03 |
MX2017007973A (es) | 2018-02-09 |
WO2016100914A1 (fr) | 2016-06-23 |
US20200101059A1 (en) | 2020-04-02 |
PT3233103T (pt) | 2021-01-18 |
US20180050027A1 (en) | 2018-02-22 |
AU2015364335B2 (en) | 2020-11-26 |
US10946008B2 (en) | 2021-03-16 |
EA036269B1 (ru) | 2020-10-21 |
EP3233103B1 (fr) | 2020-10-14 |
IL252839B (en) | 2021-03-25 |
IL252839A0 (en) | 2017-08-31 |
SG11201704808VA (en) | 2017-07-28 |
US10485797B2 (en) | 2019-11-26 |
EP3233103A1 (fr) | 2017-10-25 |
AU2015364335A1 (en) | 2017-07-20 |
CA2970723C (fr) | 2023-09-05 |
CA2970723A1 (fr) | 2016-06-23 |
CN107257686A (zh) | 2017-10-17 |
PL3233103T3 (pl) | 2021-04-19 |
ES2843323T3 (es) | 2021-07-16 |
CN107257686B (zh) | 2021-01-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA41197B1 (fr) | Traitement de le pemphigus | |
MX2021004191A (es) | Compuestos bifuncionales para degradar la tirosina cinasa de bruton (btk) mediante la trayectoria de ubiquitina proteosoma. | |
MX2021001439A (es) | Composiciones y metodos para el tratamiento de la disfuncion de la glandula de meibomio. | |
MA40768A (fr) | Dérivés d'indole mono ou di-substitué en tant qu'inhibiteurs de réplication du virus de la dengue | |
CY1110435T1 (el) | Μεθοδοι και συνθεσεις για τη θεραπεια οφθαλμικων καταστασεων με παραγωγα ρετινολης | |
WO2018115097A9 (fr) | Composition ophtalmologique pour le traitement du syndrome de l'oeil sec | |
MX2016014634A (es) | Compuestos para el tratamiento de enfermedades y trastornos oftalmicos. | |
MA38961A1 (fr) | Composés 3-phenyl-1h-pyrazolo[3,4-d]pyrimidin-4-ylamine substitués inhibiteurs de la tyrosine kinase de bruton utilisés pour traiter par exemple les maladies auto-immunes, respiratoires et inflammatoires, cancer, mastocytose et osteoporose | |
MX2017015574A (es) | Inhibidores de tirosina quinasa de bruton. | |
WO2014194254A9 (fr) | Traitement anticancer au moyen de modulateurs isoformes de la kinase p13 | |
MY187053A (en) | Envenomation therapies and related pharmaceutical compositions, systems and kits | |
TW201613919A (en) | Inhibitors of Bruton's tyrosine kinase | |
MX2015001122A (es) | Combinaciones farmaceuticas de un inhibidor de cdk4/6 y un inhibidor de b-raf. | |
MA41238A (fr) | Dérivés 5-[(pipérazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione en tant qu'inhibiteurs d'adamts pour le traitement de l'ostéoarthrit | |
NZ792518A (en) | Formulations for administration of eflornithine | |
PH12017500444A1 (en) | Pharmaceutical compositions comprising a dextromethorphan compound and quinidine for the treatment of agitation in dementia | |
WO2015095834A3 (fr) | Traitements du cancer faisant appel à des inhibiteurs des familles erk1/2 et bcl-2 | |
EA201171035A1 (ru) | Композиции, включающие модуляторы pde4, и способ их применения для лечения, профилактики и сопровождения туберкулеза | |
EA201791225A1 (ru) | Композиции и способы применения солабегрона с модифицированным высвобождением при симптомах нижних мочевых путей | |
MX2022000712A (es) | Moduladores de nlrp3. | |
MA41985B1 (fr) | Composition pour le nettoyage du côlon et le traitement de troubles gastro-intestinaux | |
WO2019004788A3 (fr) | Composition pharmaceutique comprenant de la broussochalcone a à titre de principe actif pour la prévention ou le traitement d'une maladie inflammatoire de l'intestin | |
ZA202002103B (en) | Compounds as mpges-1 inhibitors | |
MA39448A1 (fr) | (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical | |
MX2021008941A (es) | Moduladores gpr35. |